Christopher Liu

Analyst

Lucid Capital Markets

Equibles does not estimate personal net worth.

About Christopher Liu

Christopher Liu is recorded as Analyst at Lucid Capital Markets. Christopher Liu has spoken on 6 earnings calls and 1 other investor event across 5 companies, most recently for INNATE PHARMA on May 13, 2026. Those appearances were for INNATE PHARMA, Innate Pharma SA (IPHA), Relmada Therapeutics, Inc. (RLMD), Ascentage Pharma Group International (AAPG) and Cardiff Oncology, Inc. (CRDF). The companies whose calls Christopher Liu spoke on are classified in the Healthcare sector.

Christopher Liu on recent calls

“So, for the first question, are there any additional details you can give us on the profile of the drug at the go-forward dose?”

Analyst — Lucid Capital Markets, INNATE PHARMA Q1 FY2026 Earnings Call · May 13, 2026

“So, for the first question, are there any additional details you can give us on the profile of the drug at the go-forward dose?”

Analyst — Lucid Capital Markets, Earnings conference call (announced in 6-K) · May 13, 2026

“And congrats on the progress you guys have been making so far. So for my question, I was just wondering what your updated thoughts are going into this AUA update in terms of what would be a positive readout for you guys at this 12-month mark, in your opinion?”

Analyst — Lucid Capital Markets, Relmada Therapeutics, Inc. Q1 FY2026 Earnings Call · May 12, 2026

“Just wondering if you have any insight into, you know, what the go-no-go decision would be from Takeda in order to opt in from their agreement?”

Analyst — Lucid Capital Markets, Earnings conference call (announced in 6-K) · March 26, 2026

“I disconnected before, so I had to rejoin the call, so I apologize if I ask something that's already been asked. But I was wondering, you know, for the ADC, what can we expect to see from the upcoming data readouts?”

Analyst — Lucid Capital Markets, INNATE PHARMA Q4 FY2025 Earnings Call · March 26, 2026